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Until recently, aging was viewed as a fixed and irreversible process. However, in this issue of Cell Stem Cell,
Florian et al. (2012) reveal a link between increased activity of the RhoGTPaseCdc42, hematopoietic stem cell
polarity, and aging that can be regulated by pharmacological inhibition of Cdc42.Stem cells are responsible for lifelong
replenishment of mature cells, especially
in organs with high cell turnover such
as the hematopoietic system. Although
hematopoietic stem cells (HSCs) possess
the ability to self-renew for much longer
than the usual life expectancy of the
organism, there is a steady decline in their
functionality over time (Pang et al., 2011;
Rossi et al., 2005). Reduced regenerative
potential (Ergen and Goodell, 2010),
reduced production of red blood cells
and some subsets of white blood cells,
and a decreased immune response
(Linton and Dorshkind, 2004) are all
associated with increasing organismal
age. Furthermore, blood-borne diseases
such as myeloproliferative disorders
(Kiss et al., 2007) or late-onset anemia
also have a higher incidence in aged
individuals.
In our society, progressively increasing
life expectancy has led to aging of the
overall population and is concomitant
with an increased incidence of age-
related degenerative and malignant
diseases. With stem cells showing superb
potential to regenerate injured organs,
high hopes for reversing age-related
diseases have been attached to stem-
cell-based therapies. Understanding the
molecular mechanisms underlying stem
cell aging could provide a rationale for
the development of new treatments and
prevention strategies for age-related
diseases. In this issue of Cell Stem Cell,
Florian et al. provide new insights into
the molecular regulation of HSC aging
by revealing a link between intracellular
activity of the small RhoGTPase Cdc42
and decline in HSC functionality with age.
Cdc42 is a small enzyme that is able
to bind and hydrolyze GTP, and is an
important intracellular signaling molecule.
Previous studies had shown that Cdc42
displays increased physiological activityin several aged tissues in mice, such as
heart, brain, lung, liver, spleen, kidney,
and bone marrow (Wang et al., 2007). As
a logical consequence, one could specu-
late that enhanced activity of Cdc42
could, at least in part, explain the func-
tional changes in an aging organism, and
that the forced activation of Cdc42 could
lead to a premature aging phenotype. In
their current study, Geiger and colleagues
use a mouse model of elevated Cdc42
activity to test this assumption (Florian
et al., 2012). In these mice, Cdc42 activity
is increased by genetically eliminating
p50RhoGAP, a selective inhibitor of
Cdc42 (Cdc42GAP/ mice) (Wang
et al., 2007). Although these mice have
previously been shown to exhibit early
aging phenotypes in several different
tissues (Wang et al., 2007), their HSC
aging phenotype had not been explored
until now. Florian et al. show that pheno-
typic and functional changes in HSCs of
young Cdc42GAP/ mice recapitulate
the phenotypic defects observed in aged
animals, including reduced reconstitution
ability, lineage skewing, and cell polarity
defects (Florian et al., 2012).
One of the most important features of
HSCs is their ability to reconstitute the
hematopoietic system of an irradiated
host in a transplantation setting, and this
capacity declines with age. HSCs from
Cdc42GAP/ mice show a significant
reduction in hematopoietic reconstitution
ability. In addition, young Cdc42GAP/
mice showed the types of phenotypic
lineage skewing, such as reduced
lymphocyte maturation and increased
numbers of granulocytes in peripheral
blood, that are characteristically ob-
served in aged animals. Using single-cell
immunofluorescence analyses, Geiger
and colleagues demonstrate that, in
HSCs of young wild-type animals,
Cdc42 is not distributed randomly in theCell Stem Cecell cytoplasm, but is located along the
nucleus/centrosome axis at the same
pole as tubulin. In contrast, HSCs from
aged wild-type animals and from young
Cdc42GAP/ mice do not display an
asymmetric localization of Cdc42 and
tubulin, but rather these proteins were
diffusely distributed in the cell body. In
addition, the aged and Cdc42GAP/
HSCs lost their polarity, which was re-
flected by displacement of the centro-
some to the middle of the cell. These
data suggest that an intrinsic age-depen-
dent increase in Cdc42 activity could
underlie both a loss of polarity and
impaired function in HSCs during aging.
To further investigate the mechanistic
relationship between increased intrinsic
Cdc42 activity and premature aging
phenotypes, the authors turned to phar-
macological inhibitors. CASIN is a novel
molecule that specifically inhibits Cdc42
and is capable of reducing its activity in
aged HSCs to the basal level seen in
young animals. To test the effect of
Cdc42 inhibition on age-related pheno-
typic and functional changes of HSCs,
an ex vivo treatment of bone marrow
cells with CASIN was performed. Subse-
quently, CASIN-treated cells were trans-
planted for in vivo assessment. Interest-
ingly, the incubation of aged HSCs with
CASIN not only restored their polarity
but also restored a more youthful pheno-
type in terms of bone marrow and blood
cell content, as well as the repopulation
ability of aged HSCs. Surprisingly, the
effect of ‘‘rejuvenation’’ was lasting.
Even 24 weeks after the transplant of
CASIN-treated aged stem cells, the
asymmetric alignment of the cells, along
with polar Cdc42 and tubulin distribution,
was still comparable to that of young
animals. Furthermore, the repopulation
ability was retained in a second round
of bone marrow transplantation. Thisll 10, May 4, 2012 ª2012 Elsevier Inc. 481
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reminiscent of acquisition of a stable
memory phenotype. However, a lasting
memory effect, which needs to be trans-
mitted through multiple cell divisions to
daughter cells, would require inheritable
epigenetic modifications to HSC chro-
matin. As Cdc42 is known to alter acetyla-
tion of histone H4 (Alberts et al., 1998),
Florian et al. investigated whether treat-
ment with CASIN resulted in epigenetic
modification of H4. They found that,
indeed, young HSCs contain high levels
of acetylated lysine 16 on H4 (AcH4K16),
while AcH4K16 levels in aged HSCs
were substantially reduced. However,
treatment with the Cdc42-specific inhib-
itor CASIN restored levels of AcH4K16
to those observed in young HSCs.
Although the results of the study by
Florian et al. are striking and uncover
new mechanistic insights in the process
of stem cell aging with the potential
for pharmacological alteration of this
process, it would be premature to draw
conclusions about therapeutic applica-
tions at this stage. Further investigation482 Cell Stem Cell 10, May 4, 2012 ª2012 Elis needed to address many remaining
issues. For example, it is not known
whether CASIN-treated cells are able to
reduce the incidence of age-related
diseases, such as hematological malig-
nancies. In addition, the aging pheno-
types in other tissues, such as the skin,
heart, and brain, were not assayed in
this study. Because Cdc42 activity is
also increased in other tissues in this
mouse model, it would be interesting to
determine whether their aging pheno-
types can also be reversed with a similar
treatment. Finally, several outstanding
questions remain. What implications
could the discovery of a reversible aging
phenotype have for the future? Are we
getting closer to the elixir of eternal youth?
The answers to these questions will
depend on whether similar effects on
stem cell rejuvenation apply for human
hematopoietic cells and whether CASIN
can even be safely administered to
humans. Thus, many more preclinical
and clinical studies will need to be per-
formed before we can take advantage
of this important finding to devise asevier Inc.treatment that ameliorates age-related
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Human prostate cancers contain multiple cell populations marked by varying levels of the differentiation
marker prostate-specific antigen (PSA). In this issue ofCell Stem Cell, Qin et al. (2012) show that PSA/lo cells
are enriched for cells with tumor-initiating characteristics and may participate in resistance to androgen-
ablative therapies.The observation that the prostate is
capable of undergoing multiple cycles of
castration-dependent regression and
testosterone-induced regrowth suggests
the existence of hormone-independent
prostate stem cells (Isaacs, 2008).
Although unproven, it has been specu-
lated that prostate cancer may arise in
these hormone-independent stem cells.
Independent of questions regarding cell
of origin, there is increasing evidence
that prostate cancers in both rodentmodels and humans are maintained by
cellular populations that display stem
cell properties. However, the biological
nature and clinical relevance of the puta-
tive prostate cancer stem cells remains
elusive. In this issue of Cell Stem Cell,
Dean Tang and colleagues (Qin et al.,
2012) utilize a PSA promoter-driven lenti-
virus reporter system to test the relative
contribution of tumor cell subpopulations
in generating hormone refractory disease.
They demonstrate that in human prostatecancers, the PSA/lo cancer cell popula-
tion contains tumor propagating ‘‘cancer
stem cells’’ (CSCs) that resist castration.
Prostate-specific antigen (PSA) is an
androgen-regulated, tissue-specific pro-
duct of differentiated prostate cells that
is secreted into the blood. Serum PSA
has long been utilized in the early detec-
tion of prostate cancer and is a clinically
useful biomarker to follow the course of
prostate cancer in men. While serum
PSA levels positively correlate with overall
